Ubs Group Ag Clene Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Clene Inc. stock. As of the latest transaction made, Ubs Group Ag holds 170 shares of CLNN stock, worth $56. This represents 0.0% of its overall portfolio holdings.

Number of Shares

170

Previous 169 0.59%

Holding current value

$56

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.28 - $0.53 $0 - $0	1 Added 0.59%	170 $0
Q1 2023 May 12, 2023	SELL	$0.95 - $1.62 $9,065 - $15,459	-9,543 Reduced 98.26%	169 $0
Q4 2022 Feb 08, 2023	BUY	$0.92 - $1.11 $2,971 - $3,585	3,230 Added 49.83%	9,712 $9,000
Q3 2022 Nov 10, 2022	SELL	$0.33 - $4.83 $5,256 - $76,937	-15,929 Reduced 71.08%	6,482 $18,000
Q2 2022 Aug 10, 2022	BUY	$2.1 - $4.12 $24,962 - $48,974	11,887 Added 112.95%	22,411 $56,000

Q1 2022 May 16, 2022	SELL	$2.42 - $4.42 $17,273 - $31,549	-7,138 Reduced 40.41%	10,524 $41,000
Q4 2021 Feb 14, 2022	BUY	$3.95 - $7.53 $67,916 - $129,470	17,194 Added 3673.93%	17,662 $73,000
Q3 2021 Nov 15, 2021	BUY	$6.83 - $13.58 $2,663 - $5,296	390 Added 500.0%	468 $3,000
Q2 2021 Aug 13, 2021	SELL	$6.98 - $13.33 $4,362 - $8,331	-625 Reduced 88.9%	78 $1,000
Q1 2021 May 12, 2021	BUY	$6.39 - $16.3 $4,492 - $11,458	703 New	703 $9,000

Others Institutions Holding CLNN

# of Institutions

Shares Held

7.44M

Call Options Held

48.1K

Put Options Held

160K

Vanguard Group Inc Valley Forge, PA

2.62M
Shares

$864,501
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

947K
Shares

$312,355
0.0% of portfolio
Lunt Capital Management, Inc. Holladay, UT

513K
Shares

$169,244
0.11% of portfolio
Scoggin Management LP New York, NY

500K
Shares

$165,000
0.08% of portfolio
Alyeska Investment Group, L.P. Chicago, IL

474K
Shares

$156,462
0.0% of portfolio

View Full List

About Clene Inc.

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $21M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

More about CLNN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account